A Wide Wide QRS
This case report describes a patient in their 70s with shortness of breath and generalized weakness and a history of coronary artery bypass surgery, ischemic cardiomyopathy, a dual-chamber defibrillator, paroxysmal atrial fibrillation, and kidney failure while undergoing hemodialysis. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 27, 2023 Category: Internal Medicine Source Type: research
Underappreciated One-Size-FIts-All Health Inequity
This Viewpoint discusses why health priorities –tailored care, rather than the one-size-fits-all approach, is beneficial for marginalized individuals. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Provenance of Medicines and Their Clinical Benefit
This cross-sectional study examines the provenance and clinical benefit of medicines that entered the French market between 2008 and 2018 using the Prescrire and Haute Autorit é de Santé grading systems. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Risk of Bleeding Following NOAC Use in Patients With Acute Ischemic Stroke Treated With Alteplase
This Taiwanese cohort study evaluates the risk of bleeding and mortality after alteplase treatment for patients with acute ischemic stroke treated with non –vitamin K antagonist oral anticoagulants (NOACs) vs not treated with NOACs. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Oseltamivir May or May Not Reduce Hospitalizations —Reply
In Reply We thank the authors of 2 letters who sent in reflections on our systematic review and meta-analysis of oseltamivir to prevent hospitalization. Both submissions highlighted 2 key concepts that emerge from the finding that oseltamivir was not associated with reduced hospitalizations. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Oseltamivir May or May Not Reduce Hospitalizations
To the Editor We read with great interest the work by Hanula and colleagues evaluating the association between oseltamivir and hospitalization. The authors performed a meta-analysis of 15 randomized clinical trials and concluded that “…oseltamivir was not associated with a reduced risk of hospitalization but was associated with increased gastrointestinal adverse events. To justify continued use for this purpose, an adequately powered trial in a suitably high-risk population is justified.” We consider a few caveats to be wo rth discussing. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Oseltamivir May or May Not Reduce Hospitalizations
To the Editor Hanula et al reported findings of a systematic review and meta-analysis that included 15 randomized clinical trials (RCTs) of oseltamivir treatment for outpatients with influenza (age ≥12 years). The authors found no association between oseltamivir treatment of laboratory-confirmed influenza and risk of hospitalization among 6295 total participants or in subanalyses of older participants (mean age, ≥65 years; relative risk [RR], 0.99; 95% CI, 0.19-5.13) or participants with h igh-risk comorbidities (RR, 0.90; 95% CI, 0.37-2.17). (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Corrections to Meta-Analysis of Oseltamivir to Prevent Hospitalization
To the Editor On behalf of my coauthors and myself, I write to explain the correction of our Original Investigation, “Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis,” published online first on June 12, 2023, in JAMA Internal Medicine. This systematic review and meta-analysis included data from 15 randomized clinical trials and accu rately concluded that oseltamivir was not associated with reduced risk of first hospitalization compared with placebo or standard of care. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Medicare Part D Payments for Generic Imatinib
This cross-sectional study compares pharmacy acquisition costs and point-of-sale prices for generic imatinib under Medicare Part D from 2017 to 2023. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Why Some Patients Overpay for Specialty Generic Drugs
One key quid pro quo of the US pharmaceutical market is that consumers should expect to pay high prices for a set period of time for drugs offering important clinical advantages, after which generic competition quickly lowers prices closer to the cost of production. This trade-off was the intent of the Hatch-Waxman Act of 1984, the bipartisan compromise that increased brand-name drug manufacturers ’ revenues by expanding exclusivity periods while facilitating subsequent regulatory approvals of interchangeable generic versions of the drugs. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Therapeutic Benefit From New Drugs From Pharmaceutical Companies
In JAMA Internal Medicine, Osipenko and colleagues expand our knowledge about the role of the public sector in both contributing to the development of new drugs and the therapeutic gains from those drugs. They found that 27% of the 632 new drugs introduced to the French market between 2008 and 2018 originated either in the academic setting alone or in collaboration with the commercial sector. The authors also evaluated therapeutic value, applying rating scales from the French independent drug bulletin Prescrire and the Haute Autorit é de Santé, the French agency that provides a scientific opinion concerning the usefulnes...
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Error in Size of Total Population
In the Original Investigation titled “Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis,” published online on June 12, 2023, the total number of patients included in the 15 trials was 6166, not 6295. Consequently, multiple numbers needed to be adjusted by a few decimal points in the Abstract, text, Figure 2, and the eFigures in Supplement 1. None of these corrections affected the overall study findings, interpretations, or conclusions. The article was corrected online. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Repeatedly Malignant ST-Segment Elevation
This case report describes a patient in their early 50s who presented with epigastric pain and jaundice and had significantly decreased heart rate after admission. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 20, 2023 Category: Internal Medicine Source Type: research
Giving Patients the Focused Attention They Deserve
This viewpoint discusses the need for physicians to give focused attention to patients and the challenges that prevent them from doing so and suggests goals to create conditions that ensure that physicians are fully present during patient visits. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 13, 2023 Category: Internal Medicine Source Type: research
Need for AI Vigilance to Safeguard Health Care
This study examines whether artificial intelligence (AI) models can be manipulated for the generation of targeted health disinformation regarding vaccines and vaping. (Source: JAMA Internal Medicine)
Source: JAMA Internal Medicine - November 13, 2023 Category: Internal Medicine Source Type: research
